Brii BiosciencesBRIBF 34 Return-on-Tangible-Equity is -7.07% as of Dec. 2025. GuruFocus rates BRIBF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,201 Biotechnology companies, Brii Biosciences ranks better than 70.11% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Brii Biosciences's annualized net income for the quarter that ended in Dec. 2025 was $-21.17 Mil. Brii Biosciences's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $299.43 Mil. Therefore, Brii Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -7.07%.
The historical rank and industry rank for Brii Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
BRIBF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -508.19 Med: -14.45 Max: -5.86
Current: -10
During the past 7 years, Brii Biosciences's highest Return-on-Tangible-Equity was -5.86%. The lowest was -508.19%. And the median was -14.45%.
BRIBF's Return-on-Tangible-Equity is ranked better than 70.11% of 1201
companies
in the Biotechnology industry
Industry Median: -42.4
vs BRIBF: -10.00
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Brii Biosciences Return-on-Tangible-Equity Related Terms
Brii Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRIBF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Brii Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -7.07% mean?
Brii Biosciences (BRIBF) has a Return-on-Tangible-Equity of -7.07% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Brii Biosciences and its competitors. According to the industry distribution chart, Brii Biosciences ranks #359 out of 1201 companies in the Biotechnology industry, placing it in the top 29.9%.
Is Brii Biosciences' Return-on-Tangible-Equity too high?
Brii Biosciences' current Return-on-Tangible-Equity is -7.07%. Based on the distribution chart, Brii Biosciences ranks #359 out of 1201 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Brii Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #359 out of 1201 companies for Return-on-Tangible-Equity. This puts Brii Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current Return-on-Tangible-Equity is -7.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (BRIBF) has a current Return-on-Tangible-Equity of -7.07%. The current Return-on-Tangible-Equity is -7.07%. Brii Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Brii Biosciences (BRIBF), the current Return-on-Tangible-Equity is -7.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
34GF Score
Get the complete analysis for BRIBF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRIBF has been successfully added to your 
